VANCOUVER, March 4, 2013 /PRNewswire/ - Biocell Labs Inc., a wholly owned subsidiary of Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the engagement of Dr. Paula Brown to provide the Company with the expertise and assistance needed to expand its capacity into the production of novel bio-pharmaceutical products.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, "we are very pleased to have Dr. Brown join the Board of Biocell Labs Inc. with her extensive knowledge, the Company continues to deliver on its plan to become a fully integrated bioceutical company that offers cutting-edge proprietary products to the medicinal, nutraceutical and cosmetic industries."
Paula N. Brown, Ph.D., Director of Applied Research for BCIT's Natural Health & Food Products Research Group stated, "I am very excited about this opportunity to work with Biocell Labs Inc. to advance their integrated model, employing vertical automated growing systems and novel extraction technologies, to develop health and wellness products derived from medicinal plants." As far back as 2001 inconsistencies in raw materials, poor product quality and the absence of validated analytical methods have been identified as a public health risk and barrier to rigorous scientific study. Dr. Brown went on to state, "my research has grown out of a desire to apply scientific principles and advanced chemoanalytical tools to ensure consumers have confidence in the products they are ingesting."
Abattis Bioceutical Corporation would also like to announce that it has acquired from Dr. Brown a portfolio of natural health product formulas focusing on pain management, immunity & inflammation and cognitive function in exchange for 400,000 shares of Abattis.